Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. It is
classified as familial and sporadic. The dominant familial or autosomal presentation …

Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Given the acknowledged lack of success in Alzheimer's disease (AD) drug development
over the past two decades, the objective of this review was to derive key insights from the …

Alzheimer's disease (AD) is a chronic neurodegenerative disease, with the characteristics of
neurofibrillary tangle (NFT) and senile plaque (SP) formation. Although great progresses …

In the initiation or exacerbation of Alzheimer disease, the dissemination of oral
microorganisms into the brain tissue or the low‐level systemic inflammation have been …

Alzheimer's disease (AD) is the number one neurovegetative disease, but its treatment
options are relatively few and ineffective. In efforts to discover new strategies for AD therapy …

Alzheimer's disease (AD) is the most frequent case of neurodegenerative disease and is
becoming a major public health problem all over the world. Many therapeutic strategies …